Welcome to our dedicated page for HeartSciences SEC filings (Ticker: HSCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HeartSciences Inc. (HSCS) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed healthcare information technology and medical technology company, HeartSciences uses these filings to report on its financial condition, capital structure, and material corporate events related to its AI‑ECG platforms and devices.
Through forms such as the annual report on Form 10‑K and quarterly reports on Form 10‑Q, HeartSciences outlines its business focus on applying artificial intelligence to ECGs/EKGs, describes its MyoVista Insights cloud‑native ECG management platform and MyoVista wavECG device, and provides detailed financial statements and risk factor discussions. Current reports on Form 8‑K disclose specific events, including regulatory milestones, financing transactions, loan amendments, equity offerings, and notices related to Nasdaq listing requirements.
Investors can also review filings that discuss the company’s capital raising activities, such as Regulation A offerings, warrant and preferred stock issuances, and debt exchanges, as well as governance‑related items like indemnification agreements for directors and officers. These documents help explain how HeartSciences funds the development and commercialization of its AI‑ECG technologies and manages its obligations.
On Stock Titan, SEC filings for HSCS are supplemented with AI‑powered summaries that highlight key points from lengthy documents, helping readers quickly understand the significance of each filing. Users can follow new 10‑K, 10‑Q, and 8‑K submissions, along with other relevant forms, to stay informed about HeartSciences’ reported financial results, regulatory disclosures, and corporate actions.
HeartSciences Inc. is calling a virtual annual shareholder meeting on April 30, 2026 to vote on several governance and compensation matters. Shareholders of common stock and Series C preferred stock as of March 6, 2026 may participate and vote.
Key items include re-electing Andrew Simpson as the Class III director, and expanding the 2023 Equity Incentive Plan to reserve up to 1,250,000 shares of common stock plus an automatic “evergreen” increase. Shareholders will also vote on adding officer exculpation language to the certificate of formation, within limits allowed by recent Texas law.
Other proposals ask shareholders to ratify Haskell & White LLP as auditor for the year ending April 30, 2026 and to authorize potential adjournment of the meeting if additional proxy solicitation is needed. The proxy describes board structure, committee independence, director pay and current ownership, with three of five directors classified as independent.
HeartSciences Inc. reported fiscal third-quarter 2026 results and shared a business update. The healthcare IT company is focused on commercializing its MyoVista Insights ECG platform and has submitted its MyoVista wavECG device to the FDA for 510(k) premarket clearance, an important regulatory milestone.
The company reported no meaningful revenue for the quarter as it continues investing in commercialization. As of January 31, 2026, it held approximately $3.4 million in cash and cash equivalents and $2.7 million in shareholders’ equity. Full financial details are available in its Form 10-Q for the same period.
HeartSciences Inc. reported another loss-making quarter for the period ended January 31, 2026, with a nine‑month net loss of $6.4 million and minimal revenue of $4,319. Operating expenses were driven by research and development and general and administrative costs, while interest expense added further pressure.
Cash and cash equivalents were $3.4 million against $7.6 million in total assets and $4.9 million in total liabilities, leaving stockholders’ equity at $2.7 million. The company discloses substantial doubt about its ability to continue as a going concern and is relying on external financing, including a $3.6 million Streeterville note and a Series D preferred stock offering that raised about $6.7 million.
HeartSciences Inc. is soliciting shareholder votes at a virtual Annual Meeting to be held via webcast on April 30, 2026, with a record date of March 6, 2026.
The Board asks shareholders to (1) elect directors, (2) approve an increase to the 2023 Equity Incentive Plan to 1,250,000 shares plus the Evergreen Shares, (3) approve an amendment to the Certificate of Formation to permit officer exculpation as allowed by Texas law, (4) ratify the independent auditor, and (5) approve adjournment authority if votes are insufficient. Voting instructions and proxy access details are included in the Proxy Statement.
HeartSciences Inc. entered into a Note Purchase Agreement with Streeterville Capital, LLC, issuing an unsecured promissory note for $3,605,000, which includes a $600,000 original issue discount and $5,000 of transaction expenses, for gross cash proceeds of $3,000,000. The Note carries 12% annual interest, matures 18 months after issuance, and allows Streeterville, starting six months after issuance, to require monthly redemptions of up to $405,000. If the outstanding balance has not been reduced by at least $1,250,000 by the 12‑month anniversary, the outstanding balance at that time automatically increases by 5%. The Note and related agreement include customary covenants, events of default, potential default interest up to 18% (or the legal maximum), and indemnification of Streeterville, and were issued as an unregistered private placement under Section 4(a)(2) and Rule 506.
HeartSciences Inc. director David R. Wells reported a grant of 15,000 Restricted Stock Units (RSUs) on 01/12/2026. The RSUs were granted under the company’s 2023 Equity Incentive Plan at a price of $0 per unit, with each vested RSU convertible into one share of common stock.
Vesting is subject to several conditions. Shareholders must first approve plan changes that contemplate these RSU awards. After that, one-half of the RSUs vest on the one-year anniversary of the grant date, and one-eighth vests on each quarterly anniversary thereafter, so all units vest over two years if Wells continues serving on the board. Separately, 100% of the RSUs vest early if there is a Change of Control or if the company records at least $250,000 of revenue in any fiscal quarter after the grant date.
HeartSciences Inc. granted director Bruce Bent 15,000 restricted stock units (RSUs) on January 12, 2026. The RSUs were issued under the company’s 2023 Equity Incentive Plan at a price of $0 per unit, with each vested RSU delivering one share of common stock.
The award vests only if shareholders approve changes to the equity plan that contemplate these RSUs. If that condition is met, half of the RSUs vest one year after the grant date, and the remaining units vest in equal quarterly installments so that all RSUs are fully vested two years after the grant date, as long as Bent continues serving on the board.
The filing also notes that 100% of the RSUs will vest early if there is a Change of Control as defined in the plan, or if HeartSciences generates $250,000 or more of revenue in any fiscal quarter ending after the grant date.
HeartSciences Inc. approved a form of indemnification agreement on December 15, 2025 for each of its directors and executive officers. The agreement states that the company will indemnify these individuals and advance their expenses to the fullest extent permitted under Texas law and the company’s Certificate of Formation.
The arrangement also provides for continued coverage of each director and executive officer under the company’s directors’ and officers’ insurance policies. The form of indemnification agreement is filed as Exhibit 10.1.
HeartSciences Inc. disclosed that it issued a press release providing financial and operating results for the quarter ended October 31, 2025, along with other business updates. The press release is attached as Exhibit 99.1 and incorporated by reference into the report.
The company states that the information in Item 2.02 and Exhibit 99.1 is being treated as “furnished,” not “filed,” under the Exchange Act, and is not subject to the liabilities of Section 18 or automatically incorporated into other Securities Act or Exchange Act filings except by specific reference. The report is signed by Andrew Simpson, President, Chief Executive Officer and Chairman of the Board.
HeartSciences Inc. reported another loss-making quarter for the three months ended October 31, 2025 as it continues developing its AI‑driven ECG technologies. Revenue was $2,419 for the quarter and $4,319 for the six-month period, while net loss was $2,350,769 for the quarter and $4,405,763 year-to-date.
The company ended the period with $1,951,103 in cash and cash equivalents and total assets of $5,996,117. It reported an accumulated deficit of $80,533,398 and disclosed that these factors raise substantial doubt about its ability to continue as a going concern.
To fund operations, HeartSciences issued 1,912,383 Units of Series D convertible preferred stock and warrants at $3.50 per Unit for gross proceeds of approximately $6.7 million, with 1,332,544 Series D shares already converted into Common Stock. It also exchanged $2,020,000 of principal and interest on a Streeterville note into 570,626 Common shares and repaid an additional $450,000 in cash, fully retiring that note. Stockholders’ equity increased to $4,182,470 from $205,171 as of April 30, 2025, but management states current resources are insufficient to fund operations to achieve commercialization and plans to seek additional capital.